InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions

Background: The InforMing the Pathway of COPD Treatment (IMPACT) trial demonstrated lower moderate/severe exacerbation rates with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI or UMEC/VI in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Chronic Obstr Pulm Dis
Main Authors: Bourdin, Arnaud, Criner, Gerard, Devouassoux, Gilles, Dransfield, Mark, Halpin, David M.G., Han, MeiLan K., Jones, C. Elaine, Kalhan, Ravi, Lange, Peter, Lettis, Sally, Lipson, David A., Lomas, David A., Echave-Sustaeta María-Tomé, José M., Martin, Neil, Martinez, Fernando J., Quasny, Holly, Sail, Lynda, Siler, Thomas M., Singh, Dave, Thomashow, Byron, Watz, Henrik, Hanania, Nicola A.
Formato: Artigo
Idioma:Inglês
Publicado em: COPD Foundation Inc 2021
Assuntos:
Origianl Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8047616/
https://ncbi.nlm.nih.gov/pubmed/33156982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15326/jcopdf.2020.0158
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados